Saturday 17 October 2026
Export UTMD’s income statement to Excel — free account
Utah Medical Products, Inc.
UTMD Healthcare Medical Instruments & Supplies
Utah Medical Products, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, down 5.83% from fiscal 2024. In the quarter to June 2026, revenue fell 14.3%, EPS fell 10.6% and free cash flow fell 55.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
74.51
0.41
−0.55%
Follow UTMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
21.03 | 18.34 | 16.08 | 17.79 |
+8 more quarters Free account |
P/S ratio |
6.08 | 5.26 | 4.71 | 5.23 | |
P/FCF ratio |
19.19 | 15.16 | 12.66 | 14.55 | |
P/Operating CF |
158.81 | 63.51 | 52.15 | 52.07 | |
P/B ratio |
1.80 | 1.64 | 1.52 | 1.71 | |
Price to Tangible BV |
2.04 | 1.86 | 1.74 | 1.96 | |
EV/Sales |
3.69 | 2.96 | 2.51 | 3.07 | |
EV/EBITDA |
10.46 | 8.05 | 6.70 | 7.98 | |
EV/Operating CF |
11.23 | 8.32 | 6.57 | 8.38 | |
EV/FCF |
11.63 | 8.53 | 6.74 | 8.55 | |
Quick Ratio |
44.01 | 25.97 | 34.36 | 29.22 | |
Current Ratio |
48.62 | 28.64 | 37.62 | 32.06 | |
Net Debt/EBITDA |
(30.29) | (26.87) | (26.78) | (24.93) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.29 | 0.30 | 0.31 | 0.31 | |
Operating CF/Net income |
0.51 | 1.19 | 1.36 | 1.47 | |
Capex/Depreciation |
(0.56) | (0.19) | (0.14) | (0.04) | |
Research and Development Expense of Revenue |
1.81% | 1.77% | 2.34% | 1.70% | |
Selling, General and Administrative Expense of Revenue |
22.92% | 29.39% | 28.86% | 28.80% | |
Intangible Assets out of Total Assets |
0.11 | 0.11 | 0.12 | 0.13 | |
Share Based Compensation of Revenue |
0.84% | 1.38% | 1.23% | 0.96% | |
Graham Net Nets |
0.45 | 0.49 | 0.52 | 0.46 | |
Graham Number |
53.18 | 53.61 | 53.69 | 54.19 | |
Earnings Yield |
4.76% | 5.45% | 6.22% | 5.62% | |
Free Cash Flow Yield |
5.21% | 6.59% | 7.90% | 6.87% | |
Revenue per Share |
2.68 | 2.74 | 2.79 | 3.06 | |
Operating CF per Share |
0.43 | 0.98 | 1.07 | 1.21 | |
Capex per Share |
(0.04) | (0.04) | (0.03) | (0.01) | |
Free Cash Flow per Share |
0.39 | 0.94 | 1.04 | 1.20 | |
Cash per Share |
27.49 | 27.44 | 26.47 | 26.28 | |
Shareholders Equity per Share |
38.33 | 37.79 | 36.81 | 36.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
38.33 | 37.79 | 36.81 | 36.87 | |
Free Cash Flow |
1.25 | 2.98 | 3.37 | 3.85 | |
Working Capital |
98.57 | 96.87 | 95.14 | 93.52 | |
Capital Expenditures |
(0.13) | (0.13) | (0.11) | (0.03) | |
Net Current Asset Value |
98.10 | 96.37 | 94.47 | 92.81 | |
EV/EBIT |
12.96 | 10.26 | 8.47 | 9.98 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
21.39 | 18.26 | 15.90 | 16.98 | |
| Other line items | |||||
Average Receivables |
3.60 | 3.79 | 3.81 | 3.72 | |
Average Payables |
0.81 | 1.05 | 0.80 | 0.88 | |
Average Inventory |
8.62 | 8.69 | 8.37 | 8.61 | |
Average Assets |
122.69 | 123.45 | 122.54 | 125.83 | |
Average Common Equity |
119.78 | 118.71 | 118.35 | 121.22 |
Columns are period end dates